| Date | Form | Description | Docs | XBRL | Pages |
| 04/16/14 | 10-K/A | Annual report pursuant to section 13 and 15(d) |
|
41 | |
| 01/17/14 | 10-K/A | Annual report pursuant to section 13 and 15(d) |
|
|
6 |
| 01/16/14 | 10-K | Annual report pursuant to section 13 and 15(d) |
|
111 | |
| 08/27/13 | ARS | Annual report to security holders |
|
108 | |
| 01/29/13 | 10-K | Annual report pursuant to section 13 and 15(d) |
|
|
244 |
| 01/30/12 | 10-K | Annual report pursuant to section 13 and 15(d) |
|
|
94 |
| 02/14/11 | 10-K | Annual report pursuant to section 13 and 15(d) |
|
102 | |
| 01/31/11 | NT 10-K | Notice under Rule 12b25 of inability to timely file all or part of a Form 10-K, 10-KSB, or 10KT |
|
4 | |
| 06/29/10 | 10-K/A | Annual report pursuant to section 13 and 15(d) |
|
81 | |
| 03/10/10 | 10-K/A | Annual report pursuant to section 13 and 15(d) |
|
80 |
Latest News & Events
Anixa Biosciences and OntoChem Enter Next Stage of Development for Covid-19 Therapeutic
Read More...Anixa Biosciences Increases Previously Announced Bought Deal Offering of Common Stock to $22.5 Million
Read More...Anixa Biosciences Announces $10 Million Bought Deal Offering of Common Stock
Read More...